TRASTUZUMAB
CNS Metastases
Iambic Therapeutics, Incmonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the CNS Metastases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rvp-001 Reveal Pharmaceuticals Inc. | Phase 2 | B |
Selinexor Samsung Medical Center | Phase 1/2 | CC |
iam1363 Iambic Therapeutics, Inc | Phase 1 | CC |
Pembrolizumab Iambic Therapeutics, Inc | Phase 1 | CC |
Carboplatin Iambic Therapeutics, Inc | Phase 1 | CC |
T-Dxd Iambic Therapeutics, Inc | Phase 1 | CC |
Zanidatamab Iambic Therapeutics, Inc | Phase 1 | CC |
Capecitabine Iambic Therapeutics, Inc | Phase 1 | CC |
Same molecule, other indications
TRASTUZUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →